Peter Welford analyst JEFFERIES

Currently out of the existing stock ratings of Peter Welford, 28 are a BUY (59.57%), 13 are a HOLD (27.66%), 6 are a SELL (12.77%).

Peter Welford

Work Performance Price Targets & Ratings Chart

Analyst Peter Welford, currently employed at JEFFERIES, carries an average stock price target met ratio of 61.67% that have a potential upside of 29.48% achieved within 392 days.

Peter Welford’s has documented 86 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on GSK, GlaxoSmithKline PLC ADR at 12-Nov-2024.

Wall Street Analyst Peter Welford

Analyst best performing recommendations are on NVO (NOVO NORDISK A/S).
The best stock recommendation documented was for NVO (NOVO NORDISK A/S) at 8/30/2019. The price target of $22.26 was fulfilled within 14 days with a profit of $1.15 (4.91%) receiving and performance score of 3.51.

Average potential price target upside

AZN AstraZeneca PLC ADR GSK GlaxoSmithKline PLC ADR PLX Protalix Biotherapeutics CGEN Compugen GLPG Galapagos NV ADR GMAB Genmab AS NVO Novo Nordisk A/S NVS Novartis AG ADR SNY Sanofi ADR RHHBY Roche Holding Ltd ADR

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 01-Apr-2019

$105

$-88.03 (-45.60%)

$95

1 months 29 days ago
(09-Dec-2025)

13/13 (100%)

$15.18 (16.90%)

447

Buy Since 05-Sep-2023

$108.5

$-84.53 (-43.79%)

$88

2 months 13 days ago
(25-Nov-2025)

5/5 (100%)

$15.26 (16.37%)

811

Buy Since 12-Jul-2023

3 months 11 days ago
(27-Oct-2025)

6/6 (100%)

$77.4 (118.46%)

1666

Buy Since 27-Jan-2020

$87

$-106.03 (-54.93%)

$78

1 years 2 months 20 days ago
(18-Nov-2024)

9/9 (100%)

$24.91 (40.12%)

608

Buy Since 05-Jan-2023

$88

$-105.03 (-54.41%)

$89

1 years 2 months 25 days ago
(13-Nov-2024)

7/7 (100%)

$24.05 (37.61%)

303

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Peter Welford?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?